Taysha Gene Therapies Net Profit Margin 2020-2026 | TSHA
Taysha Gene Therapies net profit margin from 2020 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Taysha Gene Therapies Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-12-31 | $0.01B | $-0.11B | -1222.22% |
| 2025-06-30 | $0.01B | $-0.09B | -1175.00% |
| 2025-03-31 | $0.01B | $-0.09B | -1257.14% |
| 2024-12-31 | $0.01B | $-0.09B | -1125.00% |
| 2024-09-30 | $0.01B | $-0.02B | -230.00% |
| 2024-06-30 | $0.01B | $-0.11B | -876.92% |
| 2024-03-31 | $0.01B | $-0.12B | -842.86% |
| 2023-12-31 | $0.02B | $-0.11B | -700.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.636B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $45.423B | 17.88 |
| BridgeBio Pharma (BBIO) | United States | $13.021B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $10.175B | 25.94 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.445B | 20.49 |
| Bausch Health Cos (BHC) | Canada | $2.121B | 1.32 |
| Personalis (PSNL) | United States | $1.717B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.005B | 9.45 |
| Assembly Biosciences (ASMB) | United States | $0.508B | 24.48 |
| Sol-Gel Technologies (SLGL) | Israel | $0.169B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.042B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |